

Identification of a novel nonsense mutation in *RPI* that causes autosomal recessive retinitis pigmentosa in an Indonesian family

Anna M. Siemiatkowska,¹ Galuh D.N. Astuti,^{1,4} Kentar Arimadyo,^{4,5} Anneke I. den Hollander,^{1,2} Sultana M.H. Faradz,⁴ Frans P.M. Cremers,^{1,3} Rob W.J. Collin^{1,3}

(The first two authors contributed equally to this work)

¹Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ²Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ³Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; ⁴Division of Human Genetics, Center for Biomedical Research, Faculty of Medicine, Diponegoro University, Semarang, Indonesia; ⁵Department of Ophthalmology, Faculty of Medicine, Diponegoro University/Dr. Kariadi Hospital, Semarang, Indonesia

Purpose: The purpose of this study was to identify the underlying molecular genetic defect in an Indonesian family with three affected individuals who had received a diagnosis of retinitis pigmentosa (RP).

Methods: Clinical evaluation of the family members included measuring visual acuity and fundoscopy, and assessing visual field and color vision. Genomic DNA of the three affected individuals was analyzed with Illumina 700k single nucleotide polymorphism (SNP) arrays, and homozygous regions were identified using PLINK software. Mutation analysis was performed with sequence analysis of the retinitis pigmentosa 1 (*RPI*) gene that resided in one of the homozygous regions. The frequency of the identified mutation in the Indonesian population was determined with TaqI restriction fragment length polymorphism analysis.

Results: A novel homozygous nonsense mutation in exon 4 of the *RPI* gene, c.1012C>T (p.R338*), was identified in the proband and her two affected sisters. Unaffected family members either carried two wild-type alleles or were heterozygous carriers of the mutation. The mutation was not present in 184 Indonesian control samples.

Conclusions: Most of the previously reported *RPI* mutations are inherited in an autosomal dominant mode, and appear to cluster in exon 4. Here, we identified a novel homozygous p.R338* mutation in exon 4 of *RPI*, and speculate on the mutational mechanisms of different *RPI* mutations underlying dominant and recessive RP.

Retinitis pigmentosa (RP, OMIM 268000) represents a clinically heterogeneous group of progressive inherited retinal disorders that primarily affect rod photoreceptor cells, followed by secondary cone photoreceptor cell degeneration [1-3]. RP is the most frequent cause of inherited blindness, affecting approximately 1 in 3,500 to 1 in 5,000 people worldwide. This disease is initially characterized by night blindness followed by visual field constriction that can ultimately lead to legal blindness at a later stage [4].

In addition to the clinical diversity of RP, the disease is genetically heterogeneous. RP can be inherited in an autosomal dominant (adRP, 30% to 40%), autosomal recessive (arRP, 50% to 60%, with sporadic cases accounting for about 45% of all RP [4]), or X-linked (xLRP, 5% to 20%) [1,4], and rarely in a digenic manner [3,5]. At present, of 55 genes known to be mutated in individuals with RP, most display allelic heterogeneity, and some have been implicated

in both dominant and recessive modes of inheritance e.g., bestrophin 1 (*BEST1*), neural retina leucine zipper (*NRL*), nuclear receptor subfamily 2, group E, member 3 (*NR2E3*), rhodopsin (*RHO*), retinitis pigmentosa 1 (*RPI*), and retinal pigment epithelium-specific protein 65 kDa (*RPE65*); RetNet-Retinal Information Network; provided in the public domain by the University of Texas Houston Health Science Center, Houston, TX).

Mutations in the retinitis pigmentosa 1 gene (*RPI*, OMIM 603937) are thought to account for approximately 5.5% of adRP cases and only 1% of arRP cases, depending on the type and the position of the mutations [6]. To date, more than 50 disease-causing mutations in the *RPI* gene have been identified. They are predominantly frameshift or nonsense mutations in individuals with dominant RP, clustered in a region spanning codons 500–1053 in exon 4 [6-24]. Only a few cases of recessive *RPI* mutations in exon 4 have been reported [6,20,25-29], the majority of which is located very close to the 3' end of exon 4. Here, we report an early truncating mutation in the 5' part of exon 4 (c.1012C>T; p.R338*), which we found was homozygously present in an

Correspondence to: Rob W.J. Collin, Department of Human Genetics, Radboud University Nijmegen Medical Centre, Geert Grooteplein 10, 6525 GA Nijmegen, Netherlands; Phone: +31 24 3617431; FAX: +31 24 3668752; email: r.collin@gen.umcn.nl




Figure 1. Pedigree structure and mutation analysis of the Indonesian arRP family. A: In the family pedigree, affected individuals are indicated with filled symbols whereas unaffected relatives are indicated with open symbols. Genotypes are indicated below the pedigree symbols. M represents the c.1012C>T: (p.R338*) substitution, and + represents the wild-type allele. B: Shown are sequence chromatograms of *RPI* corresponding

to the three affected individuals (II:4, II:6, II:7), the proband's father I:1), and one unaffected sibling (II:2). The substituted nucleotides are indicated with arrows.

Indonesian family segregating arRP. A heterozygous carrier of this nonsense mutation did not display any clinical abnormalities characteristic of RP. Therefore, our findings suggest that this particular null allele of *RPI* causes recessive rather than dominant RP.

METHODS

Subjects: An Indonesian family of Javanese origin with three affected individuals and two available unaffected relatives was included in this study (Figure 1). Affected family members were diagnosed by an ophthalmologist at the Dr. Kariadi Hospital in Semarang, Central Java, Indonesia. This study was approved by the ethical review boards of the centers involved. Informed consent adhering to the tenets of the Declaration of Helsinki was obtained from all participating affected individuals and unaffected family members. In addition, 184 ethnically matched and unrelated control individuals took part in this study.

Clinical characterization: The three affected individuals (II:4, II:6, and II:7) and two unaffected relatives (I:1 and II:2) underwent a detailed ophthalmologic examination that included evaluation of visual acuity measurement, funduscopy, and fundus photography after pupillary dilation. Color vision was tested using Ishihara plates. The size and extent of the visual field defects were assessed with a Humphrey Visual Field Analyzer (Carl Zeiss Meditec, Dublin, CA). Fundus photographs were taken using a Visucam Pro NM (Carl Zeiss Meditec).

Homozygosity mapping: EDTA blood samples were obtained from all participants. Total genomic DNA was extracted from

peripheral leukocytes using a standard salting out procedure [30]. DNA aliquots of each individual were stored at -20°C . Affected individuals were genotyped on Infinium Human OmniExpress 700 K arrays (Illumina, San Diego, CA) containing approximately 700,000 single nucleotide polymorphisms (SNPs). Array experiments were performed according to the protocol provided by the manufacturer. Homozygous regions were determined using PLINK software [31], with parameters manually set at a cut-off of 1 Mb, and allowing two heterozygous SNPs and ten missing SNPs per window of 50 SNPs.

Homozygous regions were ranked based on the size of the regions. The SNP positions were derived from the UCSC Human Genome Browser build NCBI36/hg18, March 2006.

Mutation analysis: Primers for *RPI* were designed using Primer3 software [32] and are listed in Table 1. All coding exons and exon-intron boundaries of the *RPI* gene (NM_006269) were amplified with touch-down polymerase chain reaction (PCR) from 50 ng of genomic DNA. PCR reactions were performed in a volume of 25 μl containing 50 ng genomic DNA, 0.2 μM of each primer, 2 mM MgCl_2 , 1 mM deoxyribonucleotide triphosphates, PCR buffer provided by the manufacturer, and 0.5 U Taq polymerase (cat. no. 18,038-042; Invitrogen, Breda, The Netherlands).

PCR products were purified on NucleoSpin Plasmid QuickPure columns (Macherey-Nagel GmbH & Co, Duren, Germany) and analyzed either in the sense or antisense direction using dye termination chemistry (BigDye Terminator Cycle Sequencing Kit version 3.1; on a 3130 DNA automated sequencer; Applied Biosystems, Foster City, CA). Segregation

TABLE 1. PRIMER SEQUENCES FOR THE AMPLIFICATION OF THE *RPI* GENE.

Primer	Sequence (5'-3')	Product size (base pairs)
RP1 exon1 F	CCATGTATTCGCTATGGTGC	421
RP1 exon1 R	TGTCCAGGTCTACAGGCTGC	
RP1 exon2 F	GGCAGGCACAGCATCAC	434
RP1 exon2 R	CACCATTCATATCCCACACG	
RP1 exon3 F	TTCAAGCCTAGGAGGTTGTTG	357
RP1 exon3 R	ATTGAAGCATGGATTTTGCC	
RP1 exon4_1 F	GATATTTCTAACTTCTCTGCCTTCC	595
RP1 exon4_1 R	CCCTGGATGATATCTGTGTCC	
RP1 exon4_2 F	ATCAAGAGGGCAGTTTGGC	592
RP1 exon4_2 R	TTGAAGTTCTTGATACCAGTTTTG	
RP1 exon4_3 F	TCACATAATAATGGTTTGCCATC	599
RP1 exon4_3 R	TTTCTATGGAAATTCTTGGAAATC	
RP1 exon4_4 F	TCCCCTTAAAGGAGGGATAC	580
RP1 exon4_4 R	AATTGAATGATGAGCAATAGCC	
RP1 exon4_5 F	GAATGGCAAAGAAGAGTTTAGTTTC	739
RP1 exon4_5 R	ACTGAAGCTTGCAATTGGTG	
RP1 exon4_6 F	GCTTATTTGGTTCCCCTGC	678
RP1 exon4_6 R	AGAGCAACCTCCATCCAAAAG	
RP1 exon4_7 F	ACTTGAAAGCTGCTGTTGCC	659
RP1 exon4_7 R	GCTTAAATTACTGACATTTTGATGTG	
RP1 exon4_8 F	CAATGTCTGCAATACCATTGAC	658
RP1 exon4_8 R	TCCTTCATTGGTCTCCTTTTC	
RP1 exon4_9 F	TTAATCCAAGAAGAGGTAGAGGC	616
RP1 exon4_9 R	CCTGGAATTCCTGCAACATAG	
RP1 exon4_10 F	TGGAATTTCAAGTGTCCAGG	592
RP1 exon4_10 R	TGATGACTACCCTTCTCCTCTG	
RP1 exon4_11 F	CATGGTAGTGACTCAGAACCTTTTC	590
RP1 exon4_11 R	CCTTCTCCTCTAACCCCAAG	
RP1 exon4_12 F	GATAATGCCATTGGTGATATATTTG	600
RP1 exon4_12 R	CGTATTCGTCACATGTGCTTC	

analysis of the *RPI* mutation identified in the family was performed with sequence analysis. The frequency of this mutation in 184 unrelated and unaffected ethnically matched Indonesian controls was assessed by digesting PCR products with TaqI (New England Biolabs, Ipswich, MA), the recognition site of which is abolished by the alteration in *RPI*.

RESULTS AND DISCUSSION

All three affected individuals (II:4, II:6, and II:7) presented with night blindness that started at an early age. They displayed gradual constriction of their visual field and low visual acuity. Fundus examination revealed typical RP including the bone spicule-like pigment deposits in the

mid-peripheral retina and narrowing of the retinal vessels (Figure 2). The unaffected sibling (II:2) did not experience night blindness or any other symptoms of RP. Apart from slightly decreased visual acuity, which is probably age-related, the proband's father (I:1) did not display any ophthalmological symptoms either. The clinical data for all participating individuals are summarized in Table 2.

Genome-wide SNP array analysis revealed four homozygous regions larger than 1 Mb that were shared among the three affected siblings (Table 3). Whereas no obvious candidate genes resided in the three largest homozygous regions, the fourth largest homozygous region (1.3 Mb, on chromosome 8q12.1) encompassed *RPI*.




Figure 2. Fundus photographs of affected individuals. Fundus photographs of the right eye from affected individual II:4 **A**: affected individual II:6 **B**: affected individual II:7 **C**: and the unaffected father I:1 **D**: who carries the mutation heterozygously. The ages at the time of investigation of individuals II:4, II:6, and II:7 were 36, 28, and 26, respectively. Fundus examination of the affected individuals revealed typical features of retinitis pigmentosa, bone spicule-like pigmentations were found in the mid periphery of retina (indicated with arrows), and retinal vessels were attenuated (arrowheads).

Sequence analysis of *RPI* revealed a novel homozygous substitution (c.1012C>T) in the proximal portion of exon 4, replacing an arginine residue at position 338 with a stop codon (p.R338*). Sequence chromatograms and segregation analysis of the *RPI* mutation are shown in Figure 1. This nonsense alteration was not present in the unaffected sibling, and was identified heterozygously in the unaffected father, who did not show any symptoms of RP. To rule out the possibility that the second allele (inherited from the

mother) harbors a deletion of *RPI* responsible for the loss of heterozygosity, we employed copy number analysis of our genome-wide SNP data and did not find any abnormalities in this genomic region. The mutation was not detected in 184 ethnically matched and unrelated Indonesian control subjects.

The *RPI* gene consists of four exons and gives rise to a transcript of approximately 7.1 kb encoding a protein of 2,156 amino acids. The RPI protein is localized in the region of the




Figure 3. *RPI* gene and identified mutations. Schematic representation of the location of mutations in the *RPI* gene. Below are mutations responsible for dominant retinitis pigmentosa (adRP) whereas mutations above the gene cause autosomal recessive RP (arRP). The mutation identified in this study is indicated with a black rectangle. The portion of the gene that encodes the doublecortin (DCX) domains (amino acids 36–118 and 154–233) is indicated with green, and the *Drosophila melanogaster* bifocal (BIF) domain (amino acids 486–635) is depicted in red. Missense changes, for which the pathogenicity is uncertain, are not included in this scheme. Four groups of mRNA-causing mutations are marked with numbers. GR.1=protein-truncating mutations that reside in exon 2 or exon 3 (nonsense-mediated mRNA decay); GR.2=missense mutations; GR.3=protein-truncating mutations near the 3' end of the gene, preserving residual activity; GR.4=truncating mutations located in the proximal part of exon 4.

connecting cilium and axoneme of photoreceptor sensory cilia [7]. RP1 is a photoreceptor-specific microtubule-associated protein that regulates the length and stability of the photoreceptor axoneme mediated by the two putative doublecortin domains at the N-terminus of RP1 [33]. The doublecortin domain is essential for the correct localization and proper stacking of outer segment discs [34-36]. Moreover, a region

of the RP1 protein between codons 486 and 635 bears some homology to the *Drosophila melanogaster* bifocal protein that is required for normal photoreceptor morphogenesis in the fruit fly [7].

The many mutations in exon 4 of *RPI*, which cause autosomal dominant RP, all tend to cluster in a “hot spot” region between amino acid residues 500 and 1053 (Figure

TABLE 2. CLINICAL CHARACTERISTICS OF PARTICIPATING FAMILY MEMBERS

Person	Current age (y)	Gender	Age of onset (y)	Visual acuity		Fundus appearance
				OD	OS	
II:4	37	F	8	LP+	LP+	AA, BS, POD
II:6	29	F	9	1/300	1/300	AA, BS, POD
II:7	27	F	11	1/300	2/60	AA, BS
I:1	64	M	NA	20/40	20/25	Normal
II:2	42	M	NA	20/15	20/20	Normal

Clinical characteristics of affected family members carrying two RP1 variants and non-affected family members carrying one RP1 variant or two wild-type alleles. Abbreviations: AA: attenuated arterioles; BS: bone spicules; F: female; LP+: light perception; M: male; NA: not affected; OD: oculus dexter, right eye; OS: oculus sinister, left eye; POD: pale optic disc.

TABLE 3. OVERVIEW OF HOMOZYGOUS REGIONS SHARED BETWEEN THE THREE AFFECTED INDIVIDUALS.

Chr	Start position (hg 18)	End position (hg 18)	Flanking SNP 1	Flanking SNP 2	Size (Mb)	Rank	Known arRP gene in the region	Mutation (DNA)	Mutation (protein)
16	77,098,649	80,083,138	rs8056971	rs12445748	3	1			
8	50,357,738	52,191,973	rs17664823	rs10090890	2	2			
16	65,737,699	67,289,958	rs11643507	rs1886699	1.5	3			
8	55,432,038	56,765,392	rs7827900	rs7011147	1.3	4	<i>RPI</i>	c.1012C>T	p.R338*

Shown are all homozygous regions shared by three affected siblings and larger than 1 Mb. Flanking SNPs and their physical positions correspond to the hg18 NCBI genome assembly. The fourth largest homozygous region harbors *RPI*.

3) [6-24]. Since these mutations are expected to be insensitive to nonsense-mediated decay due to the absence of a downstream intron, they result in the production of truncated proteins [33]. Previously, mutant *RPI* mRNA was found to be present in a human lymphoblast cell line carrying the p.R677* variant, providing evidence that this mRNA indeed escapes the nonsense-mediated mRNA decay process. The resulting truncated proteins lack important functional domains, but are still able to interact with wild-type RPI and/or microtubule-associated proteins [35]. This hypothesis is supported by a previous study, which showed that in *Rpl-myc* mice that expressed only the 661 N-terminal amino acids of *RPI*, truncated proteins are produced and localize correctly to the axonemes of photoreceptor cells [36]. Due to the retained ability to interact with microtubule-associated proteins and/or wild-type RPI, these mutated proteins are thought to abolish the function of the normal RPI molecules in a dominant-negative fashion.

For *RPI* mutations that cause recessive RP, the story is more complex. These mutations can be clustered in four different groups (Figure 3). First, protein-truncating mutations that reside in exon 2 or exon 3 are expected to undergo nonsense-mediated decay, and therefore can be considered true loss-of-function alleles [26,28,29]. The second group consists of missense mutations that appear not to cluster [25,28]. These changes cause autosomal recessive RP because the produced proteins retain residual function and therefore are not pathogenic when present in the heterozygous state. The third group includes protein-truncating mutations near the 3' end of the gene [6,20,26,27]. Most likely, the resulting proteins display only a minor loss of their C-terminal portion, preserving the majority of functional domains, and have residual activity. Therefore, these variants are also pathogenic only when present homozygously. Finally, the most interesting group of mutations encompasses the few nonsense changes located in the proximal part of exon 4 [20,26], and includes the mutation identified in this study. Since the mRNAs deriving from these alleles are expected to escape nonsense-mediated mRNA decay, truncated RPI proteins are likely to be produced. However, unlike the adRP-causing proteins, the truncated RPI proteins apparently lack some domains that are crucial for the interactions with wild-type RPI or microtubule-associated proteins, and therefore no dominant-negative effect emerges. This is supported by the absence of clinical symptoms in the father, who carried the p.R338* mutation heterozygously.

Taken together, the results of our study indicate that early protein-truncating mutations in *RPI*, including p.R338*, cause autosomal recessive RP, supporting the idea that

haploinsufficiency is probably not causative for autosomal dominant RP. A better understanding of the pathophysiology of *RPI* mutations may ultimately lead to an improved prognosis, and provide new tools for therapeutic interventions.

ACKNOWLEDGMENTS

We gratefully acknowledge all individuals who participated in this study, and thank Marlie M.H.M. Jacobs-Camps, Mieke Kipping-Geertsema, Saskia D. van der Velde-Visser, and Willie C. Verhoef-Thuis for excellent technical assistance. We would also like to express our gratitude to the technicians of the Center for Biomedical Research (Cebior) for sample collection and preparation. This study was partially funded by Beasiswa Unggulan Ministry of Education and Culture, Republic of Indonesia. The research of A.M.S. and R.W.J.C. are supported by the Netherlands Organisation for Scientific Research (TOP-grant 196 91,209,047, to F.P.M.C. and A.I.d.H.). The research of G.D.N.A. is supported by the Directorate General for Higher Education (DIKTI) of the ministry for National Education of Indonesia, and the Radboud University Nijmegen Medical Centre in Nijmegen, The Netherlands.

REFERENCES

- Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin Eye Res* 2010; 29:335-75. [PMID: 20362068].
- Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet* 2006; 368:1795-809. [PMID: 17113430].
- Rivolta C, Sharon D, DeAngelis MM, Dryja TP. Retinitis pigmentosa and allied diseases: numerous diseases, genes and inheritance patterns. *Hum Mol Genet* 2002; 11:1219-27. [PMID: 12015282].
- Hamel C. Retinitis pigmentosa. *Orphanet J Rare Dis* 2006; 1:40-52. [PMID: 17032466].
- Dryja TP, Hahn LB, Kajiwaru K, Berson EL. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 1997; 38:1972-82. [PMID: 9331261].
- Chen LJ, Lai TY, Tam PO, Chiang SW, Zhang X, Lam S, Lai RY, Lam DS, Pang CP. Compound heterozygosity of two novel truncation mutations in RPI causing autosomal recessive retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2010; 51:2236-42. [PMID: 19933189].
- Pierce EA, Quinn T, Meehan T, McGee TL, Berson EL, Dryja TP. Mutations in a gene encoding a new oxygen-regulated photoreceptor protein cause dominant retinitis pigmentosa. *Nat Genet* 1999; 22:248-54. [PMID: 10391211].
- Sullivan LS, Bowne SJ, Birch DG, Hughbanks-Wheaton D, Heckenlively JR, Lewis RA, Garcia CA, Ruiz RS, Blanton

- SH, Northrup H, Gire AI, Seaman R, Duzkale H, Spellicy CJ, Zhu J, Shankar SP, Daiger SP. Prevalence of disease-causing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. *Invest Ophthalmol Vis Sci* 2006; 47:3052-64. [PMID: 16799052].
9. Guillonneau X, Piriev NI, Danciger M, Kozak CA, Cideciyan AV, Jacobson SG, Farber DB. A nonsense mutation in a novel gene is associated with retinitis pigmentosa in a family linked to the RP1 locus. *Hum Mol Genet* 1999; 8:1541-6. [PMID: 10401003].
 10. Bowne SJ, Daiger SP, Hims MM, Sohocki MM, Malone KA, McKie AB, Heckenlively JR, Birch DG, Inglehearn CF, Bhattacharya SS, Bird A, Sullivan LS. Mutations in the RP1 gene causing autosomal dominant retinitis pigmentosa. *Hum Mol Genet* 1999; 8:2121-8. [PMID: 10484783].
 11. Payne A, Vithana E, Khaliq S, Hameed A, Deller J, Abu-Safieh L, Kermani S, Leroy BP, Mehdi SQ, Moore AT, Bird AC, Bhattacharya SS. RP1 protein truncating mutations predominate at the RP1 adRP locus. *Invest Ophthalmol Vis Sci* 2000; 41:4069-73. [PMID: 11095597].
 12. Jacobson SG, Cideciyan AV, Iannaccone A, Weleber RG, Fishman GA, Maguire AM, Affatigato LM, Bennett J, Pierce EA, Danciger M, Farber DB, Stone EM. Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2000; 41:1898-908. [PMID: 10845615].
 13. Berson EL, Grimsby JL, Adams SM, McGee TL, Sweklo E, Pierce EA, Sandberg MA, Dryja TP. Clinical features and mutations in patients with dominant retinitis pigmentosa-1 (RP1). *Invest Ophthalmol Vis Sci* 2001; 42:2217-24. [PMID: 11527933].
 14. Baum L, Chan WM, Yeung KY, Lam DS, Kwok AK, Pang CP. RP1 in Chinese: Eight novel variants and evidence that truncation of the extreme C-terminal does not cause retinitis pigmentosa. *Hum Mutat* 2001; 17:436-44. [PMID: 11317367].
 15. Dietrich K, Jacobi FK, Tippmann S, Schmid R, Zrenner E, Wissinger B, Apfelstedt-Sylla E. A novel mutation of the RP1 gene (Lys778Ter) associated with autosomal dominant retinitis pigmentosa. *Br J Ophthalmol* 2002; 86:328-32. [PMID: 11864893].
 16. Kawamura M, Wada Y, Noda Y, Itabashi T, Ogawa S, Sato H, Tanaka K, Ishibashi T, Tamai M. Novel 2336-2337delCT mutation in RP1 gene in a Japanese family with autosomal dominant retinitis pigmentosa. *Am J Ophthalmol* 2004; 137:1137-9. [PMID: 15183808].
 17. Ziviello C, Simonelli F, Testa F, Anastasi M, Marzoli SB, Falsini B, Ghiglione D, Macaluso C, Manitto MP, Garrè C, Ciccociola A, Rinaldi E, Banfi S. Molecular genetics of autosomal dominant retinitis pigmentosa (ADRP): a comprehensive study of 43 Italian families. *J Med Genet* 2005; 42:e47. [PMID: 15994872].
 18. Gamundi MJ, Hernan I, Martínez-Gimeno M, Maseras M, García-Sandoval B, Ayuso C, Antiñolo G, Baiget M, Carballo M. Three novel and the common Arg677Ter RP1 protein truncating mutations causing autosomal dominant retinitis pigmentosa in a Spanish population. *BMC Med Genet* 2006; 7:35. [PMID: 16597330].
 19. Roberts L, Bartmann L, Ramesar R, Greenberg J. Novel variants in the hotspot region of RP1 in South African patients with retinitis pigmentosa. *Mol Vis* 2006; 12:177-83. [PMID: 16568030].
 20. Singh HP, Jalali S, Narayanan R, Kannabiran C. Genetic analysis of Indian families with autosomal recessive retinitis pigmentosa by homozygosity screening. *Invest Ophthalmol Vis Sci* 2009; 50:4065-71. [PMID: 19339744].
 21. Audo I, Mohand-Saïd S, Dhaenens CM, Germain A, Orhan E, Antonio A, Hamel C, Sahel JA, Bhattacharya SS, Zeitz C. RP1 and autosomal dominant rod-cone dystrophy: novel mutations, a review of published variants, and genotype-phenotype correlation. *Hum Mutat* 2012; 33:73-80. [PMID: 22052604].
 22. Sohocki MM, Daiger SP, Bowne SJ, Rodriguez JA, Northrup H, Heckenlively JR, Birch DG, Mintz-Hittner H, Ruiz RS, Lewis RA, Saperstein DA, Sullivan LS. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. *Hum Mutat* 2001; 17:42-51. [PMID: 11139241].
 23. Sullivan LS, Heckenlively JR, Bowne S, Zuo J, Hide WA, Gal A, Denton M, Inglehearn CF, Blanton SH, Daiger SP. Mutations in a novel retina-specific gene cause autosomal dominant retinitis pigmentosa. *Nat Genet* 1999; 22:255-9. [PMID: 10391212].
 24. Chiang SW, Wang DY, Chan WM, Tam PO, Chong KK, Lam DS, Pang CP. A novel missense RP1 mutation in retinitis pigmentosa. *Eye (Lond)* 2006; 20:602-5. [PMID: 15933747].
 25. Khaliq S, Abid A, Ismail M, Hameed A, Mohyuddin A, Lall P, Aziz A, Anwar K, Mehdi SQ. Novel association of RP1 gene mutations with autosomal recessive retinitis pigmentosa. *J Med Genet* 2005; 42:436-8. [PMID: 15863674].
 26. Riazuddin SA, Zulfiqar F, Zhang Q, Sergeev YV, Qazi ZA, Husnain T, Caruso R, Riazuddin S, Sieving PA, Hejtmancik JF. Autosomal recessive retinitis pigmentosa is associated with mutations in RP1 in three consanguineous Pakistani families. *Invest Ophthalmol Vis Sci* 2005; 46:2264-70. [PMID: 15980210].
 27. Al-Rashed M, Abu Safieh L, Alkuraya H, Aldahmesh MA, Alzahrani J, Diya M, Hashem M, Hardcastle AJ, Al-Hazzaa SA, Alkuraya FS. RP1 and retinitis pigmentosa: report of novel mutations and insight into mutational mechanism. *Br J Ophthalmol* 2012; 96:1018-22. [PMID: 22317909].
 28. Aldahmesh MA, Safieh L, Alkuraya H, Al-Rajhi A, Shamseldin H, Hashem M, Alzahrani F, Khan AO, Alqahtani F, Rahbeeni Z, Alowain M, Khalak H, Al-Hazzaa S, Meyer BF, Alkuraya FS. Molecular characterization of retinitis pigmentosa in Saudi Arabia. *Mol Vis* 2009; 15:2464-9. [PMID: 19956407].
 29. Collin RWJ, Van den Born LI, Klevering BJ, De Castro Miro M, Littink KW, Arimadyo K, Azam M, Yazar V, Zonneveld MN, Paun CC, Siemiatkowska AM, Strom TM, Hehir-Kwa JY, Kroes HY, De Faber JT, Van Schooneveld MJ, Heckenlively J, Hoyng CB, den Hollander AI, Cremers FPM.

- High-resolution homozygosity mapping is a powerful tool to detect novel mutations causative of autosomal recessive RP in the Dutch population. *Invest Ophthalmol Vis Sci* 2011; 52:2227-39. [PMID: 21217109].
30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988; 16:1215-[PMID: 3344216].
 31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81:559-75. [PMID: 17701901].
 32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol* 2000; 132:365-86. [PMID: 10547847].
 33. Liu Q, Zhou J, Daiger SP, Farber DB, Heckenlively JR, Smith JE, Sullivan LS, Zuo J, Milam AH, Pierce EA. Identification and subcellular localization of the RP1 protein in human and mouse photoreceptors. *Invest Ophthalmol Vis Sci* 2002; 43:22-32. [PMID: 11773008].
 34. Gao J, Cheon K, Nusinowitz S, Liu Q, Bei D, Atkins K, Azimi A, Daiger S, Farber D, Heckenlively JR, Pierce EA, Sullivan LS, Zuo J. Progressive photoreceptor degeneration, outer segment dysplasia, and rhodopsin mislocalization in mice with targeted disruption of the retinitis pigmentosa-1 (Rpl) gene. *Proc Natl Acad Sci USA* 2002; 99:5698-703. [PMID: 11960024].
 35. Liu Q, Lyubarsky A, Skalet JH, Pugh EN Jr, Pierce EA. RP1 is required for the correct stacking of outer segment discs. *Invest Ophthalmol Vis Sci* 2003; 44:4171-83. [PMID: 14507858].
 36. Liu Q, Zuo J, Pierce EA. The retinitis pigmentosa 1 protein is a photoreceptor microtubule-associated protein. *J Neurosci* 2004; 24:6427-36. [PMID: 15269252].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 03 October 2012. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.